Lukang Pharmaceutical receives approval for amlodipine besylate tablets

Shandong Lukang Pharmaceutical (SSE:600789) announced that it has been granted drug registration certificates for its Amlodipine Besylate Tablets (2.5mg and 5mg) from the National Medical Products Administration of China. The drug, a calcium channel blocker, is indicated for the treatment of hypertension and angina. The company stated that the approval will enhance its market competitiveness, while also noting that the market for Amlodipine Besylate Tablets in China saw approximately CNY 4.671 billion in sales in 2024. As of the announcement date, Lukang Pharmaceutical has invested approximately CNY 8.2991 million in the research and development of the drug. The company cautioned that sales are subject to market and policy uncertainties.